aacr.org· AACR·2026-04-21 03:10· 2026-04-21Score60

Third New Drugs on the Horizon Session: Four Preclinical Molecules

Reading

Medicinal chemistry beyond KRAS: CDK2, WEE1, SERD

CID-078 is a cyclin A/B macrocycle; Circle Pharma reported early activity and acceptable safety at AACR.

In brief

Four investigational drugs disclosed: CID-078 (Circle Pharma), AMX-883 (Amphista), JNJ-89862175 (Johnson & Johnson) and IPN01203 (Ipsen).

Conference abstracts

CT023NCT06577987matched by 代号 CID-078

Early clinical activity from the phase 1 evaluation of CID-078, a novel Cyclin A/B-RxL inhibitor, in patients with advanced solid tumors

Afshin Dowlati, Timothy A Yap, Antonio Giordano, Nehal J. Lakhani, William B McKean, Ildefonso Ismael Rodriguez Rivera, Vivek Subbiah, Kyaw Zin Thein, Judy S. Wang, Jinshu Fang, Li-Fen Liu, Peadar Cremin, Lukas Makris, Li-Pen Tsao, Lisa M. Kopp, Shivaani Kummar

Read the abstract →

Source: aacr.org · aacr.org